254 related articles for article (PubMed ID: 34092788)
1. Obesity shapes selection for driver mutations in cancer.
Tang C; Castillon VJ; Waters M; Fong C; Park T; Boscenco S; Kim S; Schultz N; Ostrovnaya I; Gusev A; Jee J; Reznik E
medRxiv; 2024 Jan; ():. PubMed ID: 38260500
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenesis: The more we seek to know the more we need to know - Challenges in the post Genomic Era.
Kovvali G; Shiff S; Telang N; Das K; Kohgo Y; Narayan S; Li H
J Carcinog; 2003 Jan; 2(1):1. PubMed ID: 12605710
[No Abstract] [Full Text] [Related]
3. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier.
Safdar NS; Thompson EF; Gilks CB; Isacson C; Bennett JA; Clarke B; Young RH; Oliva E
Am J Surg Pathol; 2021 Aug; 45(8):1038-1046. PubMed ID: 34115671
[TBL] [Abstract][Full Text] [Related]
4. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.
Liu S; Wu M; Wang F
J Cancer; 2021; 12(13):3976-3996. PubMed ID: 34093804
[TBL] [Abstract][Full Text] [Related]
5. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma.
Loukovaara M; Pasanen A; Bützow R
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206702
[TBL] [Abstract][Full Text] [Related]
6. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM; Calo CA
Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
[TBL] [Abstract][Full Text] [Related]
7. Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers.
Song Y; Pan S; Li K; Chen X; Wang ZP; Zhu X
Semin Cancer Biol; 2022 Oct; 85():219-233. PubMed ID: 34098106
[TBL] [Abstract][Full Text] [Related]
8. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
[TBL] [Abstract][Full Text] [Related]
9. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Cao W; Ma X; Fischer JV; Sun C; Kong B; Zhang Q
Biomark Res; 2021 Jun; 9(1):49. PubMed ID: 34134781
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
12. PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis.
Wang L; Liu Z; Zhang W; Zhang A; Qu P
Biomed Res Int; 2021; 2021():9923434. PubMed ID: 34124265
[TBL] [Abstract][Full Text] [Related]
13. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
[TBL] [Abstract][Full Text] [Related]
15. Low Expression of RILPL2 Predicts Poor Prognosis and Correlates With Immune Infiltration in Endometrial Carcinoma.
Liu J; Xu M; Wu Z; Yang Y; Yuan S; Liang J; Zhu H
Front Mol Biosci; 2021; 8():670893. PubMed ID: 34095226
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors.
Prieto-Potin I; Idrovo F; Suárez-Gauthier A; Díaz-Blázquez M; Astilleros-Blanco de Córdova L; Chamizo C; Zazo S; Carvajal N; López-Sánchez A; Pérez-Buira S; Aúz-Alexandre CL; Manso R; Plaza-Sánchez J; de Lucas-López V; Pérez-González N; Martín-Valle S; Cristóbal I; Casado V; García-Foncillas J; Rojo F
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010253
[TBL] [Abstract][Full Text] [Related]
17. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
18. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.
Liontos M; Svarna A; Theofanakis C; Fiste O; Andrikopoulou A; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4862-4873. PubMed ID: 34898589
[TBL] [Abstract][Full Text] [Related]
19. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.
Mori S; Gotoh O; Kiyotani K; Low SK
J Hum Genet; 2021 Sep; 66(9):853-868. PubMed ID: 34092788
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
